A first-in-human prostate cancer study in the Journal of Molecular Imaging and Biology showed initial safety, biodistribution and dosimetry results with [18F]DCFPyL, a second-generation fluorine-18 labeled small-molecule prostate-specific membrane antigen (PSMA) inhibitor. The imaging biomarker has been developed at Johns Hopkins University in Baltimore by study co-author Martin G. Pomper, M.D., Ph.D.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now